JP2023055884A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023055884A5 JP2023055884A5 JP2023015050A JP2023015050A JP2023055884A5 JP 2023055884 A5 JP2023055884 A5 JP 2023055884A5 JP 2023015050 A JP2023015050 A JP 2023015050A JP 2023015050 A JP2023015050 A JP 2023015050A JP 2023055884 A5 JP2023055884 A5 JP 2023055884A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- cell
- exogenous gene
- engineered
- endogenous
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000001744 T-lymphocyte Anatomy 0.000 claims 16
- 238000000034 method Methods 0.000 claims 14
- 108090000623 proteins and genes Proteins 0.000 claims 13
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 8
- 210000004027 cell Anatomy 0.000 claims 4
- 108010042407 Endonucleases Proteins 0.000 claims 3
- 102000004533 Endonucleases Human genes 0.000 claims 3
- 102100028970 HLA class I histocompatibility antigen, alpha chain E Human genes 0.000 claims 3
- 102100028967 HLA class I histocompatibility antigen, alpha chain G Human genes 0.000 claims 3
- 108010024164 HLA-G Antigens Proteins 0.000 claims 3
- 101000986085 Homo sapiens HLA class I histocompatibility antigen, alpha chain E Proteins 0.000 claims 3
- 239000003153 chemical reaction reagent Substances 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 3
- 101710163270 Nuclease Proteins 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 238000003780 insertion Methods 0.000 claims 2
- 230000037431 insertion Effects 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 210000004986 primary T-cell Anatomy 0.000 claims 2
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 claims 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 1
- 108091033409 CRISPR Proteins 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 108020004414 DNA Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 210000002865 immune cell Anatomy 0.000 claims 1
- 238000009169 immunotherapy Methods 0.000 claims 1
- 230000010354 integration Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 210000000822 natural killer cell Anatomy 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000001568 sexual effect Effects 0.000 claims 1
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2017/076798 WO2018073391A1 (en) | 2016-10-19 | 2017-10-19 | Targeted gene insertion for improved immune cells therapy |
| EPPCT/EP2017/076798 | 2017-10-19 | ||
| EP2018053343 | 2018-02-09 | ||
| EPPCT/EP2018/053343 | 2018-02-09 | ||
| JP2020521596A JP7621795B2 (ja) | 2017-10-19 | 2018-03-09 | 改善された免疫細胞療法のためのｎｋ阻害物質遺伝子の標的指向遺伝子組み込み |
| PCT/EP2018/055957 WO2019076486A1 (en) | 2017-10-19 | 2018-03-09 | TARGETED GENE INTEGRATION OF NK INHIBITOR GENES FOR ENHANCED IMMUNE CELL THERAPY |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020521596A Division JP7621795B2 (ja) | 2017-10-19 | 2018-03-09 | 改善された免疫細胞療法のためのｎｋ阻害物質遺伝子の標的指向遺伝子組み込み |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023055884A JP2023055884A (ja) | 2023-04-18 |
| JP2023055884A5 true JP2023055884A5 (enExample) | 2023-10-05 |
Family
ID=66173541
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020521596A Active JP7621795B2 (ja) | 2017-10-19 | 2018-03-09 | 改善された免疫細胞療法のためのｎｋ阻害物質遺伝子の標的指向遺伝子組み込み |
| JP2023015050A Pending JP2023055884A (ja) | 2017-10-19 | 2023-02-03 | 改善された免疫細胞療法のためのｎｋ阻害物質遺伝子の標的指向遺伝子組み込み |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020521596A Active JP7621795B2 (ja) | 2017-10-19 | 2018-03-09 | 改善された免疫細胞療法のためのｎｋ阻害物質遺伝子の標的指向遺伝子組み込み |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US12209125B2 (enExample) |
| EP (2) | EP3684919A1 (enExample) |
| JP (2) | JP7621795B2 (enExample) |
| KR (2) | KR20200075851A (enExample) |
| CN (1) | CN111511903B (enExample) |
| AU (2) | AU2018353112B2 (enExample) |
| CA (1) | CA3084476A1 (enExample) |
| IL (1) | IL273828B2 (enExample) |
| MX (1) | MX2020004444A (enExample) |
| WO (2) | WO2019076486A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3059643A1 (en) * | 2017-04-13 | 2018-10-18 | Cellectis | New sequence specific reagents targeting ccr5 in primary hematopoietic cells |
| EP3662055A1 (en) * | 2017-08-02 | 2020-06-10 | Autolus Limited | Cells expressing a chimeric antigen receptor or engineered tcr and comprising a nucleotide sequence which is selectively expressed |
| JP7621795B2 (ja) | 2017-10-19 | 2025-01-27 | セレクティス | 改善された免疫細胞療法のためのｎｋ阻害物質遺伝子の標的指向遺伝子組み込み |
| EP3802578A4 (en) | 2018-06-01 | 2022-03-23 | Washington University | SUPPRESSION OF CYTOKINE RELEASE SYNDROME IN CHIMERIC ANTIGEN RECEPTOR CELL THERAPY |
| US10724052B2 (en) * | 2018-09-07 | 2020-07-28 | Crispr Therapeutics Ag | Universal donor cells |
| CN110055224B (zh) * | 2019-04-03 | 2023-06-30 | 深圳市体内生物医药科技有限公司 | 一种基因修饰的免疫细胞及其制备方法和应用 |
| US20220249558A1 (en) | 2019-04-30 | 2022-08-11 | Crispr Therapeutics Ag | Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19 |
| KR20220016474A (ko) | 2019-05-01 | 2022-02-09 | 주노 쎄러퓨티크스 인코퍼레이티드 | 변형된 ｃｄ247 유전자 자리로부터 키메라 수용체를 발현하는 세포, 관련 폴리뉴클레오타이드 및 방법 |
| AU2020307667A1 (en) * | 2019-06-27 | 2022-01-20 | Crispr Therapeutics Ag | Use of chimeric antigen receptor T cells and NK cell inhibitors for treating cancer |
| US11118195B2 (en) * | 2019-09-05 | 2021-09-14 | Crispr Therapeutics Ag | Universal donor cells |
| AU2020340622A1 (en) | 2019-09-05 | 2022-03-03 | Crispr Therapeutics Ag | Universal donor cells |
| US20230127263A1 (en) * | 2019-09-20 | 2023-04-27 | The University Of North Carolina At Chapel Hill | Modified t cells and methods of preparing the same |
| CN115315273A (zh) | 2020-01-14 | 2022-11-08 | 辛德凯因股份有限公司 | Il-2直向同源物及其使用方法 |
| US20230332104A1 (en) * | 2020-06-11 | 2023-10-19 | Novartis Ag | Zbtb32 inhibitors and uses thereof |
| WO2021263075A1 (en) * | 2020-06-26 | 2021-12-30 | St. Jude Children's Research Hospital, Inc. | Methods of generating an activation inducible expression system in immune cells |
| WO2022020860A2 (en) * | 2020-07-24 | 2022-01-27 | Board Of Regents, The University Of Texas System | Engineered t cells and tumor-infiltrating lymphocytes to increase tumor killing |
| EP3943097A1 (en) * | 2020-07-24 | 2022-01-26 | AB2 Bio SA | Car-t cell therapy |
| WO2022112596A1 (en) | 2020-11-30 | 2022-06-02 | Cellectis Sa | Use of aminoquinoline compounds for higher gene integration |
| WO2022143783A1 (en) * | 2020-12-29 | 2022-07-07 | Edigene Therapeutics (Beijing) Inc. | Methods of identifying t-cell modulating genes |
| AU2021414405A1 (en) | 2020-12-31 | 2023-08-10 | Crispr Therapeutics Ag | Universal donor cells |
| IL308012A (en) * | 2021-04-30 | 2023-12-01 | Cellectis Sa | Anti-MUC1 for novel chimeric antigen receptors and genetically engineered immune cells for solid tumor immunotherapy |
| KR20240027117A (ko) * | 2021-07-01 | 2024-02-29 | 닝보 티-맥시멈 바이오파마슈티컬스 컴퍼니 리미티드 | B7h3을 표적으로 하는 항원 결합 폴리펩티드 및 이의 응용 |
| CN117940465A (zh) * | 2021-08-12 | 2024-04-26 | 苏州克睿基因生物科技有限公司 | 经修饰的细胞、其制备方法及应用 |
| CN119095606A (zh) * | 2022-04-25 | 2024-12-06 | 小利兰·斯坦福大学托管委员会 | 用于预防t细胞耗竭的组合物和方法 |
| CN115820697B (zh) * | 2022-09-23 | 2024-07-30 | 中国海洋大学 | 一种免疫细胞及其制备方法和应用 |
| AU2024259472A1 (en) * | 2023-04-20 | 2025-11-13 | Peter Maccallum Cancer Institute | Compositions and methods for immunotherapy - ii |
| WO2024258835A1 (en) * | 2023-06-16 | 2024-12-19 | The Trustees Of Columbia University In The City Of New York | Removal of endogenous tcr chains for enhanced tcr-based immunotherapies |
| TW202509218A (zh) * | 2023-07-12 | 2025-03-01 | 亨利傑克森軍方醫學基金會 | 用於抑制自然殺手細胞之組合物及方法 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US5858358A (en) | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
| FR2646438B1 (fr) | 1989-03-20 | 2007-11-02 | Pasteur Institut | Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration |
| WO1994024277A1 (en) | 1993-04-13 | 1994-10-27 | Sloan-Kettering Institute For Cancer Research | Protection of human bone marrow from high dose antifolate therapy using mutated human dihydrofolate reductase dna |
| US7175843B2 (en) | 1994-06-03 | 2007-02-13 | Genetics Institute, Llc | Methods for selectively stimulating proliferation of T cells |
| US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
| US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
| US6642043B1 (en) | 1996-03-12 | 2003-11-04 | Sloan-Kettering Institute For Cancer Research | Double mutants of dihydrofolate reductase and methods of using same |
| WO2000046386A2 (en) | 1999-02-03 | 2000-08-10 | The Children's Medical Center Corporation | Gene repair involving the induction of double-stranded dna cleavage at a chromosomal target site |
| US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| DK1257632T3 (da) | 2000-02-24 | 2008-01-28 | Xcyte Therapies Inc | Samtidig stimulering og opkoncentrering af celler |
| US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
| EP1590468A2 (en) | 2003-01-28 | 2005-11-02 | Cellectis | Use of meganucleases for inducing homologous recombination ex vivo and in toto in vertebrate somatic tissues and application thereof |
| WO2004083379A2 (en) | 2003-03-14 | 2004-09-30 | Walters Richard E | Large volume ex vivo electroporation method |
| CA2783351C (en) | 2009-12-10 | 2021-09-07 | Regents Of The University Of Minnesota | Tal effector-mediated dna modification |
| WO2012098238A1 (en) * | 2011-01-21 | 2012-07-26 | Novimmune S.A. | Combination therapies and methods using anti-cd3 modulating agents and anti-il-6 antagonists |
| US20140134195A1 (en) * | 2011-04-20 | 2014-05-15 | University Of Washington Through Its Center For Commercialization | Beta-2 microglobulin-deficient cells |
| CA3133545C (en) | 2012-05-25 | 2023-08-08 | Cellectis | Use of pre t alpha or functional variant thereof for expanding tcr alpha deficient t cells |
| US20150283233A1 (en) * | 2012-06-15 | 2015-10-08 | Gencia Corporation | Compositions and Methods for Enhancing Immune Responses |
| ES2824024T3 (es) * | 2012-10-10 | 2021-05-11 | Sangamo Therapeutics Inc | Compuestos modificadores de células T y usos de los mismos |
| DK3004337T3 (da) * | 2013-05-29 | 2017-11-13 | Cellectis | Fremgangsmåde til konstruktion af T-celler til immunoterapi ved brug af RNA-guidet Cas nuklease-system |
| ES2782125T3 (es) | 2014-03-11 | 2020-09-10 | Cellectis | Método para generar linfocitos T compatibles para trasplante alogénico |
| AU2015330017A1 (en) * | 2014-10-07 | 2017-04-27 | Cellectis | Method for modulating car-induced immune cells activity |
| US11186824B2 (en) * | 2015-03-11 | 2021-11-30 | Cellectis | Methods for engineering allogeneic T cell to increase their persistence and/or engraftment into patients |
| AU2016246698B2 (en) * | 2015-04-06 | 2022-06-02 | Regeneron Pharmaceuticals, Inc. | Humanized T cell mediated immune responses in non-human animals |
| HK1254190A1 (zh) | 2015-05-08 | 2019-07-12 | President And Fellows Of Harvard College | 通用供体干细胞和相关方法 |
| GB2557123B (en) * | 2015-07-31 | 2021-11-03 | Univ Minnesota | Modified cells and methods of therapy |
| US11091780B2 (en) * | 2015-09-18 | 2021-08-17 | The Regents Of The University Of California | Methods for autocatalytic genome editing and neutralizing autocatalytic genome editing and compositions thereof |
| KR20250141836A (ko) | 2015-11-04 | 2025-09-29 | 페이트 세러퓨틱스, 인코포레이티드 | 만능 세포의 유전자 조작 |
| ES2901795T3 (es) | 2015-12-04 | 2022-03-23 | Juno Therapeutics Inc | Métodos y composiciones relacionadas con la toxicidad asociada con la terapia celular |
| CA3010869A1 (en) * | 2016-01-15 | 2017-07-20 | Etubics Corporation | Methods and compositions for t-cell immunotherapy |
| CN109804064A (zh) * | 2016-09-29 | 2019-05-24 | 南克维斯特公司 | 具有降低的免疫原性的hla i类缺陷的nk-92细胞 |
| CN106636090B (zh) | 2016-10-11 | 2019-08-09 | 上海优卡迪生物医药科技有限公司 | 人源白细胞介素6的siRNA、重组表达CAR-T载体及其构建方法和应用 |
| CN108148863B (zh) | 2016-12-05 | 2019-12-17 | 上海优卡迪生物医药科技有限公司 | 一种封闭il6r的用于缓解crs的car-t转基因载体及其构建方法和应用 |
| JP7621795B2 (ja) | 2017-10-19 | 2025-01-27 | セレクティス | 改善された免疫細胞療法のためのｎｋ阻害物質遺伝子の標的指向遺伝子組み込み |
-
2018
- 2018-03-09 JP JP2020521596A patent/JP7621795B2/ja active Active
- 2018-03-09 US US16/755,082 patent/US12209125B2/en active Active
- 2018-03-09 WO PCT/EP2018/055957 patent/WO2019076486A1/en not_active Ceased
- 2018-03-09 CA CA3084476A patent/CA3084476A1/en active Pending
- 2018-03-09 MX MX2020004444A patent/MX2020004444A/es unknown
- 2018-03-09 KR KR1020207014099A patent/KR20200075851A/ko not_active Ceased
- 2018-03-09 AU AU2018353112A patent/AU2018353112B2/en active Active
- 2018-03-09 IL IL273828A patent/IL273828B2/en unknown
- 2018-03-09 EP EP18719441.0A patent/EP3684919A1/en active Pending
- 2018-03-09 KR KR1020247043433A patent/KR20250007705A/ko active Pending
- 2018-03-09 CN CN201880082153.1A patent/CN111511903B/zh active Active
- 2018-04-16 AU AU2018351689A patent/AU2018351689B2/en active Active
- 2018-04-16 US US16/755,093 patent/US12221478B2/en active Active
- 2018-04-16 EP EP18722412.6A patent/EP3673049A1/en active Pending
- 2018-04-16 WO PCT/EP2018/059692 patent/WO2019076489A1/en not_active Ceased
-
2023
- 2023-02-03 JP JP2023015050A patent/JP2023055884A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023055884A5 (enExample) | ||
| JP2020537528A5 (enExample) | ||
| JP6929791B2 (ja) | エピゲノム編集のための組成物および方法 | |
| CN114729384A (zh) | 工程化腺相关病毒衣壳 | |
| JP2019536447A5 (enExample) | ||
| JP2022115941A (ja) | 遺伝子組換えにより内在性ｆｏｘｐ３遺伝子の発現が安定化されたｃｄ４ ｔ細胞を使用した自己免疫疾患の治療方法 | |
| CN106244557B (zh) | 定点突变ApoE基因与LDLR基因的方法 | |
| US11141471B2 (en) | Universal donor checkpoint inhibitor silenced/gene edited cord blood killer cells | |
| JPWO2019178422A5 (enExample) | ||
| CN103343120A (zh) | 一种小麦基因组定点改造方法 | |
| JP2021534810A (ja) | Ｒｎａを編集する方法および組成物 | |
| JP2018512162A5 (enExample) | ||
| KR20170084334A (ko) | 화학적 변형을 갖는 가이드 rna | |
| JP2018522072A5 (enExample) | ||
| JPWO2019178421A5 (enExample) | ||
| JP2024506751A (ja) | 遺伝子サイレンシング | |
| JP2022513586A (ja) | 抗ｌｉｖ１免疫細胞癌療法 | |
| JPWO2020163365A5 (enExample) | ||
| JP2009521218A (ja) | 異なる長さのパリンドロームセグメントを含むパリンドローム免疫調節オリゴヌクレオチド（ｉｍｏ（ｔｍ））の免疫賦活作用 | |
| US20250122471A1 (en) | Engineered antigen presenting cells and uses thereof | |
| JP2015524413A5 (enExample) | ||
| JPWO2019178420A5 (enExample) | ||
| JP2022519070A (ja) | 免疫療法の改善のための遺伝子調節組成物及び遺伝子調節方法 | |
| JP2023532917A (ja) | Ｂ細胞のｂ２ｍ遺伝子座を編集するための方法および組成物 | |
| US20240010977A1 (en) | Methods for enhancing therapeutic efficacy of isolated cells for cell therapy |